{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:50:28Z","timestamp":1793238628439,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Perlecan is a 500\u00a0kDa proteoglycan residing in the extracellular matrix of endothelial basement membranes with five distinct protein domains and three heparan sulfate chains. The complex structure of perlecan and the interaction it has with its local environment accounts for its various cellular and tissue-related effects, to include cartilage, bone, neural and cardiac development, angiogenesis, and blood brain barrier stability. As perlecan is a key contributor to extracellular matrix health involved in many tissues and processes throughout the body, dysregulation of perlecan has the potential to contribute to various neurological and musculoskeletal diseases. Here we review key findings associated with perlecan dysregulation in the context of disease. This is a narrative review article examining perlecan\u00e2\u20ac\u2122s role in diseases of neural and musucloskeletal pathology and its potential as a therapeutic index. Literature searches were conducted on the PubMed database, and were focused on perlecan\u2019s impact in neurological disease, to include ischemic stroke, Alzheimer\u2019s Disease (AD) and brain arteriovenous malformation (BAVM), as well as musculoskeletal pathology, including Dyssegmental Dysplasia Silverman-Handmaker type (DDSH), Schwartz-Jampel syndrome (SJS), sarcopenia, and osteoarthritis (OA). PRISMA guidelines were utilized in the search and final selection of articles.Increased perlecan levels were associated with sarcopenia, OA, and BAVM, while decreased perlecan was associated with DDSH, and SJS. We also examined the therapeutic potential of perlecan signaling in ischemic stroke, AD, and osteoarthritic animal models. Perlecan experimentally improved outcomes in such models of ischemic stroke and AD, and we found that it may be a promising component of future therapeutics for such pathology. In treating the pathophysiology of sarcopenia, OA, and BAVM, inhibiting the effect of perlecan may be beneficial. As perlecan binds to both \u00ce\u00b1-5 integrin and VEGFR2 receptors, tissue specific inhibitors of these proteins warrant further study. In addition, analysis of experimental data revealed promising insight into the potential uses of perlecan domain V as a broad treatment for ischemic stroke and AD. As these diseases have limited therapeutic options, further study into perlecan or its derivatives and its potential to be used as novel therapeutic for these and other diseases should be seriously considered.<\/jats:p>","DOI":"10.3389\/fphys.2023.1189731","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T08:51:03Z","timestamp":1685609463000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Perlecan: a review of its role in neurologic and musculoskeletal disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Tessa R.","family":"Lavorgna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Gressett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley H.","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Bix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer's disease facts and figures","volume":"13","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/15537","article-title":"Perlecan is essential for cartilage and cephalic development","volume":"23","author":"Arikawa-Hirasawa","year":"1999","journal-title":"Nat. Genet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/86941","article-title":"Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene","volume":"27","author":"Arikawa-Hirasawa","year":"2001","journal-title":"Nat. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/0092-8674(94)90031-0","article-title":"Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis","volume":"79","author":"Aviezer","year":"1994","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1083\/jcb.147.5.1109","article-title":"Perlecan maintains the integrity of cartilage and some basement membranes","volume":"147","author":"Costell","year":"1999","journal-title":"J. Cell Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.3390\/ijms22126574","article-title":"Heparan sulfate proteoglycans in viral infection and treatment: A special focus on SARS-CoV-2","volume":"22","author":"De Pasquale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B7","first-page":"649","article-title":"Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells","volume":"73","author":"Dodge","year":"1995","journal-title":"Lab. Invest."},{"key":"B8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/03008207.2015.1045297","article-title":"The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy","volume":"56","author":"Douglass","year":"2015","journal-title":"Connect. Tissue Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"25947","DOI":"10.1074\/jbc.M111.243626","article-title":"Endorepellin, the angiostatic module of perlecan, interacts with both the \u03b12\u03b21 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): A dual receptor antagonism","volume":"286","author":"Goyal","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.matbio.2016.09.003","article-title":"A current view of perlecan in physiology and pathology: A mosaic of functions","author":"Gubbiotti","year":"2017","journal-title":"Matrix Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3390\/ijms23041934","article-title":"Regulation of FGF-2, FGF-18 and transcription factor activity by perlecan in the maturational development of transitional rudiment and growth plate cartilages and in the maintenance of permanent cartilage homeostasis","volume":"23","author":"Hayes","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.matbio.2012.02.006","article-title":"Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation","volume":"31","author":"Ishijima","year":"2012","journal-title":"Matrix Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/WNR.0b013e3283554c5c","article-title":"Perlecan domain V is upregulated in human brain arteriovenous malformation and could mediate the vascular endothelial growth factor effect in lesional tissue","volume":"23","author":"Kahle","year":"2012","journal-title":"Neuroreport"},{"key":"B14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.matbio.2013.01.004","article-title":"Synovial perlecan is required for osteophyte formation in knee osteoarthritis","volume":"32","author":"Kaneko","year":"2013","journal-title":"Matrix Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.scr.2013.12.009","article-title":"Perlecan is required for FGF-2 signaling in the neural stem cell niche","volume":"12","author":"Kerever","year":"2014","journal-title":"Stem Cell Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1161\/STROKEAHA.108.533216","article-title":"Brain arteriovenous malformation biology relevant to hemorrhage and implication for therapeutic development","volume":"40","author":"Kim","year":"2009","journal-title":"Stroke"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1172\/JCI46358","article-title":"Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents","volume":"121","author":"Lee","year":"2011","journal-title":"J. Clin. Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/genes9110556","article-title":"Modular proteoglycan perlecan\/HSPG2: Mutations, phenotypes, and functions","volume":"9","author":"Martinez","year":"2018","journal-title":"Genes (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.3390\/ijms23095148","article-title":"Fractone stem cell niche components provide intuitive clues in the design of new therapeutic procedures\/biomatrices for neural repair","volume":"23","author":"Melrose","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1083\/jcb.201807178","article-title":"Perlecan regulates pericyte dynamics in the maintenance and repair of the blood-brain barrier","volume":"218","author":"Nakamura","year":"2019","journal-title":"J. Cell Biol."},{"key":"B21","volume-title":"Osteoarthritis: National clinical guideline for care and management in adults","year":"2008"},{"key":"B22","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.rec.2021.07.010","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3233\/JAD-130683","article-title":"Perlecan domain V inhibits amyloid-\u03b2 induced brain endothelial cell toxicity and restores angiogenic function","volume":"38","author":"Parham","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fphar.2012.00155","article-title":"Perlecan and the blood-brain barrier: Beneficial proteolysis?","volume":"3","author":"Roberts","year":"2012","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1161\/CIR.0b013e3182456d46","article-title":"Executive summary: Heart disease and stroke statistics--2012 update: A report from the American heart association","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"Fso142","DOI":"10.4155\/fsoa-2016-0034","article-title":"Use of FGF-2 and FGF-18 to direct bone marrow stromal stem cells to chondrogenic and osteogenic lineages","volume":"2","author":"Shu","year":"2016","journal-title":"Future Sci. OA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1093\/hmg\/ddn213","article-title":"Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz-Jampel syndrome neuromyotonia","volume":"17","author":"Stum","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12975-020-00800-5","article-title":"Perlecan domain-V enhances neurogenic brain repair after stroke in mice","volume":"12","author":"Trout","year":"2021","journal-title":"Transl. Stroke Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3390\/ijms21020679","article-title":"Review of alterations in perlecan-associated vascular risk factors in dementia","volume":"21","author":"Trout","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/acel.12169","article-title":"Apoptosis in capillary endothelial cells in ageing skeletal muscle","volume":"13","author":"Wang","year":"2014","journal-title":"Aging Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ydbio.2016.08.029","article-title":"Knockdown of the pericellular matrix molecule perlecan lowers in situ cell and matrix stiffness in developing cartilage","volume":"418","author":"Xu","year":"2016","journal-title":"Dev. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.matbio.2009.04.010","article-title":"Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis","volume":"28","author":"Zoeller","year":"2009","journal-title":"Matrix Biol."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2023.1189731\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T08:51:08Z","timestamp":1685609468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2023.1189731\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":32,"alternative-id":["10.3389\/fphys.2023.1189731"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2023.1189731","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"article-number":"1189731"}}